MAbMods™ Anti-Mouse CD152 (CTLA-4) [Clone 9H10 (LALAPG)]

Mouse CTLA-4-human IgG1 fusion protein

This recombinant monoclonal antibody is aseptically packaged (0.2um filtered) and formulated in 0.01 M PBS (phosphate buffered saline) (150 mM NaCl) pH 7.0 - 7.5 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant antibodies and isotype controls are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Recombinant antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid repeated freeze thaw cycles.

Research Use Only (RUO)

2-8°C

This product is a chimeric antibody built on the parental 9H10 clone. It keeps the original variable domains unchanged but replaces the Syrian hamster IgG1 constant region with a mouse IgG2a, κ backbone. This constant region carries the LALA-PG Fc-silencing mutations, which eliminate binding to endogenous murine Fcy receptors and C1q. As a result, the antibody cannot trigger antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). That makes this product well suited for studying CTLA-4 antagonism on its own, without the confounding effects of Fc-mediated regulatory T cell (Treg) depletion or other effector activity.

Because the constant region is matched to the host species, this chimeric format is less immunogenic in mouse models than a xenogeneic antibody. It is also less likely to provoke anti-drug antibodies (ADAs). In addition, recombinant production gives a defined sequence that does not undergo the genetic drift seen in hybridoma lines, which supports greater lot-to-lot consistency and reproducibility.

CTLA4 (Cytotoxic T-Lymphocyte Antigen 4) also known as CD152, is a protein which is expressed on the surface of Helper T cells and plays an important regulatory role in the immune system.¹ CTLA4 is a member of the immunoglobulin superfamily, expressed on the surface of Helper T cells. CTLA4 transmits an inhibitory signal to T cells.^{2, 3} CTLA4 is potentially therapeutic in autoimmune diseases⁴, such as rheumatoid arthritis, HIV, autoimmune thyroid disease, multiple sclerosis and may also be useful during organ transplantation and cancer treatment. The 9H10 antibody has been shown to promote T cell co-stimulation by blocking CTLA-4 binding to the B7 co-receptors, allowing for CD28 binding.

Activated T cells